Diffrence in Thromboprofilaksis in Elderly Ostoepenic Hip Fractures According to Mobility Status by Genetic Analysis

Not Applicable

Recruiting

• Conditions: Hip Fracture of Intertrochanteric Type; Thromboembolic Event; Osteopenia; Thrombosis Embolism

• Registration Number: NCT06959017
• Lead Sponsor: Saglik Bilimleri Universitesi

Brief Summary

Hip fracture is a common and severe disease in elderly patients. The question of the study is whether elderly patients with severe osteopenia have significantly lower levels of the collagen-binding protein Hsp47 than relatively mobile patients due to advanced immobility before the fracture, and whether they participants have a similar risk of VTE to the normal population despite having had a hip fracture and surgery.

Detailed Description

In this study, the investigators aimed to prospectively measure the Hsp 47 gene expression levels in patients scheduled for surgery due to intertrochanteric femur fracture and healthy volunteers in the same age group and compare the results with the literature.

Also the complications prior or after surgery will be compared.

Study Timeline

• Study Start: 2024-11-01
• Status Verified: 2025-04
• Study First Submitted: 2025-04-18
• Study First Submitted QC: 2025-04-26
• Study First Posted: 2025-05-06
• Last Update Submitted: 2025-05-07
• Last Update Posted: 2025-05-13
• Primary Completion: 2025-06-01
• Study Completion: 2025-12-01

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 90

Inclusion Criteria

• >65 years of age
• Interthrocanteric femur fracture AO Type 31A1, 31A2, 31A3
• Patients treated proksimal femoral nail
• Minor trauma
• Fracture mobility score 1,2,3,4,5
• Inial thrombocytes count 150.000-450.000 /µL

Exclusion Criteria

• Body mass index >40
• Fracture mobility score 6 (unknown type)
• stage 4 chronic kidney disease
• Patients with rheumatological diseases
• Patients at serious risk of VTE(Venous thromboembolism) (according to the International Society on Thrombosis and Hemostasis, categorization of venous thromboembolism) :
• Active Hematologic Cancer
• Antiphospholipid syndrome
• History of recurrent thrombosis (DVT)
• Paroxysmal nocturnal hemoglobinuria

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: CROSSOVER

Primary Outcome Measures

Name	Time	Method
HSP 47	Gene expression analysis will be performed once samples are collected from all participants.	HSP 47 (SERPİNH1, ROCK1) gene expression analysis

Secondary Outcome Measures

Name	Time	Method
Thromboembolie	from fracture occur up to one year	Thromboembolic events

Trial Locations

Locations (1)

Prof Dr emil Tascıoglu City Hospital; 🇹🇷 İstanbul, Şişli, Turkey